UPDATE: Cantor Fitzgerald Lowers Endo Pharmaceuticals' PT

According to a research report published this morning, Cantor Fitzgerald has lowered Endo Pharmaceuticals'

PT from $50 to $39. In the report, Cantor Fitzgerald commented, "The company reported revenues of $690.6M vs. $700.5M consensus and EPS of $0.87, which was in-line with consensus estimates. Of more concern, the performance of the generics and device segments lagged expectations and investors should look for initiatives towards the back half of the year (international device launches, new Women's Health introductions, and the pickup of Opana ER and Voltaren Gel) to drive revenues within guidance parameters. We think there is too much execution required." Cantor Fitzgerald maintains its Hold rating on Endo Pharmaceuticals, which closed yesterday at $34.66.